Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces thatBracknor Investment Group has advised the Company that they will convert a portion of the first tranche of the Convertible Loan Notes issued to them on 22 February 2017 into new ordinary shares of 25p each in the share capital of the Company. Further details of the conversion are set out below.
| Number of CLN converted: 10 |
| Total nominal value of the CLN converted: £100,000 |
| Conversion price: £0.2789 |
| Number of shares issued from the conversion: 358,551 |
| Shares issued for the satisfaction of the conversion fees: 10,756 |
Application will be made for admission to trading on AIM of the 369,307 new Ordinary Shares deriving from the conversion of the CLN and in satisfaction of the conversion fees and it is expected that Admission will occur on or around 18 April 2017.
Total voting rights
Following Admission, the Company’s enlarged issued share capital will comprise 73,385,807 Ordinary Shares, with voting rights. The Company does not hold any Ordinary Shares in treasury. Therefore the total number of Ordinary Shares in the Company with voting rights will be 73,385,807. This figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA’s Disclosure Guidance and Transparency Rules.
| Advanced Oncotherapy Plc | www.avoplc.com |
| Dr. Michael Sinclair, Executive Chairman | Tel: +44 20 3617 8728 |
| Nicolas Serandour, CEO | |
| Stockdale Securities (Nomad & Joint Broker) | |
| Antonio Bossi / David Coaten | Tel: +44 20 7601 6100 |
| Stifel Nicolaus Europe (Joint Broker) | |
| Jonathan Senior / Ben Maddison | Tel: +44 20 7710 7600 |
| Walbrook PR (Financial PR & IR) | Tel: +44 20 7933 8780 or avo@walbrookpr.com |
| Paul McManus / Anna Dunphy | Mob: +44 7980 541 893 / Mob: +44 7876 741 001 |